TiGenix welcomes manufacturing licence for European facility

Following a cGMP inspection by authorities in the Netherlands, TiGenix has obtained manufacturing approval for human medicinal products for its European manufacturing plant in Sittard-Geleen in the Netherlands. The facility provides TiGenix with manufacturing capabilities to support anticipated growth in demand for ChondroCelect for cartilage repair, and has sufficient capacity for the production of the company's advanced stem cell therapy products.

This article is tagged to:
Sector: Medical Devices
Geography: Belgium

Access all of our latest analysis, data and forecasts - request a trial